Navigating the Rapidly Evolving Classification and Treatment Landscape of Secondary Acute Myeloid Leukemia (AML) Subtypes

---

ONLINE

Friday, June 14, 2024, 12:00 AM - Saturday, June 14, 2025, 11:59 PM


AMA PRA Category 1 Credits™ (1.00 hours), ANCC - Nursing Contact Hour(s) (1.00 hours), Non-Physician Attendance (1.00 hours)

Secondary acute myeloid leukemia (sAML) typically emerges as a consequence of a prior clonal disorder within the hematopoietic system. This condition commonly results from myelodysplasia-related changes (referred to as AML-MRC) or exposure to cytotoxic chemotherapy or radiation therapy used to treat unrelated malignancies, known as therapy-related AML (t-AML). In terms of burden, prognostic factors, diagnostic criteria, and treatments, substantial differences exist between sAML and de novo AML. Further, sAML has been linked to less favorable outcomes when compared with de novo AML. Historically, the treatment of sAML was very limited, as patients typically did not receive desirable outcomes from older agents. Fortunately, the sAML treatment paradigm is beginning to shift due to new and emerging therapies. Clinicians must be aware of these practice-changing developments and tailored management strategies to significantly impact patient outcomes.

1. Identify the prognostic factors in secondary acute myeloid leukemia (AML) that contribute to its heightened severity compared with patients diagnosed with de novo AML
2. Outline the criteria for diagnosing secondary AML.
3. Evaluate the latest clinical trial findings for new and emerging therapies that have the potential to significantly enhance treatment results in patients with secondary AML.
4. Integrate novel agents into secondary AML treatment plans based on recent clinical evidence and individualized factors

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designations

The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The University of Texas MD Anderson Cancer Center designates this enduring material will award 1.0 Nursing Contact Hours.

View the accessibility policy for The University of Texas MD Anderson Cancer Center.

 

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.